Loading company
Pulse Biosciences, Inc.
PLSE · Nasdaq · ·
Next earnings: November 4, 2026
$50.91-2.7%Sep 29 close
- 1M
- +7.0%
- 6M
- +159.3%
- 1Y
- +187.6%
- 5Y
- +126.3%
Pulse Biosciences, Inc. is the 21st largest of 48 graded companies. Showing 5 of them, including PLSE itself. 2 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Intuitive Surgical, Inc.ISRG | A+ | $145.6B | $11B | 28.4% | $3.2B | 47.27 |
| Becton, Dickinson And CompanyBDX | B | $49.6B | $23.3B | 4.0% | $2.6B | 54.82 |
| ResMed Inc.RMD | B+ | $32.2B | $5.7B | 26.9% | $1.6B | 21.37 |
| Alcon Inc.ALC | B | $31.9B | $9.5B | 10.3% | $1.7B | 33.05 |
| Pulse Biosciences, Inc.PLSE | D- | $3.6B | $1.2M | -6,755.8% | -$61.4M | — |
43 more medical instruments and supplies companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Pulse Biosciences, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
PLSE · Nasdaq · ·
Next earnings: November 4, 2026
$50.91-2.7%Sep 29 close